With a pipeline from Gerngross’ Adimab, Arsanis hunts a $58M IPO for antibody development work
After burning through slightly more than $81 million, a biotech co-founded by Adimab’s Tillman Gerngross has pencilled in a $57.5 million raise from an IPO …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
